Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study

N. Katsumata, K. Noda, S. Nozawa, R. Kitagawa, R. Nishimura, S. Yamaguchi, D. Aoki, N. Susumu, H. Kuramoto, T. Jobo, K. Ueki, M. Ueki, I. Kohno, K. Fujiwara, Y. Sohda, F. Eguchi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status ≤2 entered the study. Docetaxel 70 mg m-2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

Original languageEnglish
Pages (from-to)999-1004
Number of pages6
JournalBritish Journal of Cancer
Volume93
Issue number9
DOIs
Publication statusPublished - 2005 Oct 31

Keywords

  • Docetaxel
  • Endometrial cancer
  • Phase II

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study'. Together they form a unique fingerprint.

  • Cite this

    Katsumata, N., Noda, K., Nozawa, S., Kitagawa, R., Nishimura, R., Yamaguchi, S., Aoki, D., Susumu, N., Kuramoto, H., Jobo, T., Ueki, K., Ueki, M., Kohno, I., Fujiwara, K., Sohda, Y., & Eguchi, F. (2005). Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. British Journal of Cancer, 93(9), 999-1004. https://doi.org/10.1038/sj.bjc.6602817